BioNTech initiates clinical trial of mRNA-based malaria vaccine candidate
on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said.
The Phase 1 trial is expected to enrol 60 volunteers in the United States with no history of malaria to assess the vaccine candidate at three-dose levels. Known as BNT165b1, it is the first vaccine candidate from BioNTech's malaria project, which will also establish vaccine production in Africa. The effort is one of several focused on addressing the mosquito-borne disease that kills over 600,000 each year, most of them children in Africa. The complicated structure and lifecycle of the malaria parasite has long stymied efforts to develop vaccines.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
BioNTech starts human trials on a vaccine for malariaThe company’s planned vaccine production site in Kigali, Rwanda will help produce the malaria shot
Read more »
BioNTech initiates clinical trial of mRNA-based malaria vaccine candidate - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday.
Read more »
Surging inflation drives UK shoppers to German discounters for Christmas groceriesAldi and Lidl are attracting more Christmas shoppers amid a cost-of-living squeeze, leading traditional supermarkets like Tesco to cut prices and offer loyalty incentives
Read more »
More than 1,500 cars an hour expected from Gauteng to KZN from FridayTraffic volumes from Gauteng to KwaZulu-Natal are expected to increase at the start of the Christmas weekend on Friday.
Read more »